1. Home
  2. TRTX vs SLDB Comparison

TRTX vs SLDB Comparison

Compare TRTX & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TPG RE Finance Trust Inc.

TRTX

TPG RE Finance Trust Inc.

HOLD

Current Price

$8.40

Market Cap

659.4M

Sector

Real Estate

ML Signal

HOLD

Logo Solid Biosciences Inc.

SLDB

Solid Biosciences Inc.

HOLD

Current Price

$10.61

Market Cap

674.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRTX
SLDB
Founded
2014
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
659.4M
674.4M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
TRTX
SLDB
Price
$8.40
$10.61
Analyst Decision
Buy
Strong Buy
Analyst Count
4
11
Target Price
$9.83
$16.36
AVG Volume (30 Days)
698.7K
2.5M
Earning Date
04-28-2026
05-12-2026
Dividend Yield
11.55%
N/A
EPS Growth
N/A
34.97
EPS
N/A
N/A
Revenue
N/A
$8,094,000.00
Revenue This Year
$8.78
N/A
Revenue Next Year
$4.14
N/A
P/E Ratio
$14.82
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.57
$3.79
52 Week High
$9.85
$10.88

Technical Indicators

Market Signals
Indicator
TRTX
SLDB
Relative Strength Index (RSI) 46.79 77.01
Support Level $8.35 $6.38
Resistance Level $8.72 N/A
Average True Range (ATR) 0.15 0.65
MACD -0.02 0.30
Stochastic Oscillator 30.61 99.11

Price Performance

Historical Comparison
TRTX
SLDB

About TRTX TPG RE Finance Trust Inc.

TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating-rate first mortgage loans that are secured by high-quality commercial real estate properties undergoing some form of transition and value creation.

About SLDB Solid Biosciences Inc.

Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.

Share on Social Networks: